RxDoctor Payments Data

Brenda Kozak

Adult Health · Wyomissing, PANPI 1477508075

Payments from drug & device makers

$2,080in general payments, 2019–2025

Across 89 payments — averaging $23.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$578
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$405
  • AstraZeneca$377
  • Bayer$125
  • Boston Scientific$116
  • Johnson & Johnson$90
  • plus $389 from 11 others

What the payments were for

  • Food & beverage$2,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,080 in reported general payments places this provider in the 80th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,275
Medicare patients
117
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BrilintaTicagrelor33$15,559
EntrestoSacubitril/Valsartan15$15,003
EliquisApixaban21$11,959
XareltoRivaroxaban14$10,003
Amiodarone Hcl153$1,912
Prasugrel Hcl52$1,594
ClopidogrelClopidogrel Bisulfate256$1,211
Rosuvastatin Calcium82$806
Bisoprolol Fumarate59$744
Atorvastatin Calcium149$700
Nitroglycerin77$636
Flecainide Acetate30$534
Metoprolol Succinate40$471
Isosorbide Mononitrate ErIsosorbide Mononitrate85$464
Potassium Chloride28$215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$377$15,55933 claims
NovartisEntresto$71$15,00315 claims
PfizerEliquis$12$11,95921 claims
Johnson & JohnsonXarelto$90$10,00314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →